Joint protection strategies help prevent the chronic arthritis that historically plagued hemophilia patients. Proper body mechanics, assistive devices when needed, maintaining healthy weight ...

In patients with inflammatory arthritis, excessive growth of synovium is part of ... a rare condition in which very aggressive growth of the synovium occurs hemophilia There are two basic forms of ...

Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

Jivi antihemophilic factor is now approved for children aged 7-12 with hemophilia A, expanding its previous approval for older patients. Hemophilia A is more common than hemophilia B, with early ...

Arthritis is identified as an independent risk factor for prostate cancer, with significant associations found in various analyses. The study utilized NHANES data and Mendelian randomization to ...

In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later ...

Hemophilia is a rare genetic condition that prevents your blood from clotting and can lead to bleeding problems. People with hemophilia can have bleeding episodes that happen without trauma and ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and more on those who work around the clock to take care of them.

VIJAYAWADA: The State government is committed to ensuring uninterrupted care for citizens with rare and chronic disorders like hemophilia, Health Minister Y Satya Kumar Yadav said while ...

Hemophilia, a condition where the blood does not clot properly, can lead to severe and prolonged bleeding. This condition, rooted in genetic mutations, often affects quality of life and requires ...

The approval is based on data from the Alfa-PROTECT and PROTECT Kids studies, demonstrating Jivi’s safety and efficacy in children aged 7 to under 12 years with severe hemophilia A. This ...